Search results
Results From The WOW.Com Content Network
Rucaparib is a first-in-class pharmaceutical drug ... The studies for these two trials are still going on and the estimated dates for the first results are range ...
For premium support please call: 800-290-4726 more ways to reach us
Earlier this month, Clovis Oncology Inc (NASDAQ: CLVS) had a Type A meeting with the FDA to discuss its plans for a supplemental marketing application for Rubraca (Rucaparib) as a first-line ...
Decitabine/cedazuridine is indicated for treatment of adults with myelodysplastic syndromes, including previously treated and untreated, de novo and secondary myelodysplastic syndromes with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia) and intermediate-1 ...
Iniparib (BSI 201, developed by Sanofi) was determined in 2012 not to be a true PARP inhibitor [36] [37] and failed trial for triple negative breast cancer. [35] In 2013 Sanofi disclosed that iniparib failed to help squamous cell lung cancer patients in a phase III trial, prompting the company to end research into the once-promising compound ...
Updated Phase 2a Open-Label Trial Results Cartesian today also announced positive updated results from retreated participants enrolled in the Phase 2a open-label portion of the trial. Two participants were previously retreated, and experienced rapid improvement in clinical scores and maintained minimum symptom expression for up to one year ...
She has also led early-stage trials that determined the safety of the combination of rucaparib and the chemotherapy drug carboplatin for advanced solid tumours, [9] Following successful clinical trials, [10] Rucaparib was given accelerated approval in the US by the FDA in 2016 [11] and received a conditional licence by the EU in 2018. [12] [13 ...
On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation. The ...